



LARGE CLINICAL EXPERIENCE
+700 MILLION
PATIENT DAYS
EU APPROVED
BIOSIMILAR MEDICINES

2006

1st WORLDWIDE APPROVAL
IN THE EU


BIOSIMILAR FILGRASTIM
+44% PATIENT ACCESS
IN THE EU (2006 - 2013)


AVAILABLE TO PATIENTS
IN **+60 COUNTRIES**
AROUND THE WORLD

A GROWING OPPORTUNITY
FOR HEALTHCARE BUDGETS
A **€78 BN** MARKET
WILL OPEN TO
COMPETITION BY 2020 


1st BIOSIMILAR MONOCLONAL
ANTIBODY
EU - 2013

USE OF BIOSIMILARS
SAVINGS FROM
€11,8 UP TO **33,4 BN**
FOR 8 EU COUNTRIES (2007-2020)

OVER **15** EUROPEAN COUNTRIES
HAVE **MANUFACTURING SITES** FOR
BIOSIMILAR MEDICINES
OR BIOSIMILAR
CANDIDATES UNDER
DEVELOPMENT/EVALUATION 